Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A‑ROS1 rearrangement: A case report

The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto‑oncogene 1 (ROS1)‑rearranged non‑small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47‑year‑old woman with lung adenocarcinoma harboring a rare HLA_A‑ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A‑ROS1‑rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1‑rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.